We're all fatheads. That is, our brain cells are packed with fat molecules, more of them than almost any other cell type. Still, if the brain cells' fat content gets too high, they'll be in trouble. In a recent study in mice, ...
Apr 8, 2013
0
0
The India Supreme Court's rejection of a patent for an improved version of a costly cancer drug by Novartis AG could have big implications for the world's largest drugmakers.
Apr 1, 2013
0
0
India's Supreme Court is to rule Monday on a landmark patent case involving Swiss drugmaker Novartis AG that focuses on demands by major companies that their investments be protected, against Indian companies that say they ...
Mar 31, 2013
0
0
(AP)—Anglo-Swedish pharmaceutical company AstraZeneca has settled a patent dispute with Watson Laboratories, Inc., removing a threat against its top-selling cholesterol-control drug, Crestor.
Mar 25, 2013
0
0
The Supreme Court will soon decide whether generic drug manufacturers can be sued in state court for a drug's design defects after federal officials approved the brand-name version.
Mar 19, 2013
0
0
Drugmaker Pfizer Inc. said Tuesday that a new patent on one of its top drugs, anti-inflammatory painkiller Celebrex, extends its U.S. patent protection by 18 months, potentially bringing the company a few billion dollars ...
Mar 5, 2013
0
0
India's patent appeals office has rejected Bayer AG's plea to stop the production of a cheaper generic version of a patented cancer drug in a ruling that health groups say is an important precedent for getting inexpensive ...
Mar 5, 2013
3
0
German pharmaceuticals giant Bayer, maker of Aspirin, vowed Monday to fight a ruling by the patent authorities in India allowing a local company to produce and sell a generic copy of its anti-cancer drug Nexavar.
Mar 4, 2013
0
0
The widely held belief that the UK supply of innovative new medicines has conspicuously dwindled in recent decades, is not borne out by the evidence, reveals research published in the online journal BMJ Open.
Feb 20, 2013
0
0
In the fifth Series paper, researchers led by Professor Hans Hogerzeil from the University of Groningen in the Netherlands say that most NCDs could be treated with a small range of inexpensive, off-patent medicines, and suggest ...
Feb 11, 2013
0
0
